To provide long-term capital appreciation.
Name | % Net Assets |
---|---|
Astrazeneca | 4.6% |
GlaxoSmithKline | 4.5% |
Smiths Group | 4.3% |
Logica | 4.3% |
Carnival | 4.2% |
Imperial Tobacco Group | 4.1% |
BT Group | 4.1% |
Bunzl | 4.0% |
Unilever | 4.0% |
BG Group | 4.0% |
Key | % Net Assets |
---|---|
Astrazeneca | 4.6% |
GlaxoSmithKline | 4.5% |
Smiths Group | 4.3% |
Logica | 4.3% |
Other | 82.3% |
Date | 18-Mar-2022 |
---|---|
NAV | 304.48p |
Currency | GBP |
Change | 4.34p |
% | 1.45% |
YTD change | 304.48p |
YTD % | n/a |
Fund Inception | 05/11/2001 |
---|---|
Fund Manager | Marvyn Douglas |
TER | 0.78 (31-Jan-2012) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.70% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.20 |
You are here: research